INTRODUCTION {#sec1-1}
============

Major orthopedic surgeries are commonly associated with marked blood loss, and a subsequent need for blood transfusion is often encountered. The causes of bleeding are multifactorial, increased fibrinolytic activity being one of them.\[[@ref1][@ref2]\] Although bleeding from these surgical sites is usually controllable, there may be significant blood loss. Several approaches\[[@ref3]\] have been used to reduce intraoperative blood loss, including: Hypotensive anesthesia which has its own detrimental consequences.\[[@ref4][@ref5]\] The use of allogeneic blood products increases the rate of transmission of infectious diseases, modulates the immune response, and increases the risk of postoperative infection. The alternate approaches are administration of antifibrinolytic agents such as tranexamic acid (TA) perioperatively to stabilize the multiple micro-clots that form within the surgical wound.\[[@ref6][@ref7]\]

TA is a synthetic derivative of the amino acid lysine (4-aminoethyl cyclohexane carboxylic acid),\[[@ref8]\] that exerts its antifibrinolytic effect through the reversible blockade of lysine binding sites on plasminogen molecules, thereby reducing the conversion of plasminogen to plasmin. Hence, it blocks the dissolution of hemostatic fibrin, which stabilizes fibrin structure and thus may decrease the blood loss secondary to increase fibrinolysis.\[[@ref9][@ref10]\] TA has been used in neuro, orthopedic, cardiac, spine and maxillofacial surgeries and has reduced the amount of blood loss and subsequent need for blood transfusion.\[[@ref11]--[@ref16]\] The aim of this study is to evaluate the efficacy of intraoperative IV TA on postoperative blood loss following surgeries for hip and femoral fractures.

METHODS {#sec1-2}
=======

Ninety patients (ASA grade I/II patients between 18 and 80 years, weighing 40-100 kg) undergoing surgery for femoral fracture like open reduction internal fixation (ORIF), hemiarthroplasty, total hip replacement (THR) was included. Patients with chronic disease like Rheumatoid arthritis, ischemic heart disease, malignancy, history of any previous thromboembolic episodes, hemoglobin \<8 g/dl were excluded from the study. The study was approved by the institutional Ethics Committee and written informed consent was obtained from each patient.

They were allocated to two groups. Randomization was done by opaque sealed envelope technique.

Group T: Patients received inj. TA 10 mg/kg body weight.

Group P: Patients received physiological saline 1 ml/kg body weight.

Preoperatively, the hemoglobin concentration, bleeding time, clotting times were measured on the day before operation. All patients in the study group received a bolus intravenous injection of 500 mg TA through 50 ml syringe (as weight of all studied patients was almost equal) during 10 min about 15 min before incision, followed by a continuous infusion of 1 mg/kg/h dissolved in 1 lit of saline until the completion of surgery. Patients in the placebo group received normal saline a bolus intravenous injection of 50 ml about 15 min before the surgery followed by a continuous infusion of 1 liter of saline until the surgery completed. Drug and normal saline were loaded in 50 ml syringe by an independent anesthetist. The anesthetist administrating the drug was unaware of 50 ml being given. Surgery was performed under combined spinal epidural anesthesia with 0.5% bupivacaine heavy (hyperbaric) in 15 mg dose. During induction, an epidural catheter was also inserted to provide postoperative analgesia.

Hemodynamics (heart rate; systolic, diastolic and mean arterial blood pressure (MABP)) was noted starting from preoperational to shifting at regular intervals of 30 min. Ringer\'s solution was used as the replacement fluid for the estimated intraoperative blood volume lost in a 3:1 ratio. There was no significant difference in amount of fluid in both the groups. Postoperative hemoglobin concentration (on day 0 and day 2) and volume of blood in the drain (when the patient entered into recovery room on the day of operation at 20:00 h) were measured. The number of units of packed red cells transfused during the hospital stay was recorded, and any thromboembolic and other complications were documented. A criterion for blood transfusion was a reduction in hemoglobin exceeding 25% of preoperative level.

For tests of differences between quantitative data, two-sided t-tests were used. In the text, data are presented as mean±standard deviation (SD) and *P*\<0.05 are considered significant.

RESULTS {#sec1-3}
=======

There were no significant differences between the patients with respect to age, sex, duration and type of surgery and preoperative mean hemoglobin concentration \[[Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}\]. Neither heart rate nor MABP has statistically significant difference or results (*P*\>0.05).

###### 

Patient characteristics, laboratory and surgical data
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The drains were removed in the evening of the first postoperative day. Mean volume of blood in the drain was 39.33± as compared to 91.11± in placebo group showing a highly significant reduction in postoperative blood loss (*P*=0.01) \[[Figure 2](#F2){ref-type="fig"}\]. Mean fall in hemoglobin at day 0 was 2.99±3.457 in the study group as compared to 7.70±6.05 in the placebo that has *P* value 0.01 making it significant finding \[[Figure 3](#F3){ref-type="fig"}\]. Similar to this fall in hemoglobin at day 2 in the study group was 0.3578±0.744 and in the placebo was 2.7122±2.70 with *P* value 0.000 again showing statistically significant \[[Table 2](#T2){ref-type="table"}\].

###### 

Postoperative volume of blood in drain and % fall in hemoglobin
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In our study out of 45 patients, 18 patients who fell in the placebo group required blood transfusion and while seven patients out of 45 in the study group need a transfusion (*P*=0.01). No significant complications like thromboembolic episodes were encountered in both the groups.

DISCUSSION {#sec1-4}
==========

Several studies have investigated the effect of TA on intraoperative and postoperative blood loss in patients undergoing orthopedic surgeries like total knee replacement (TKR), THR, spinal surgeries and hip fractures but the efficacy of such treatment has not yet been clearly established. In this study, we found that preoperative administration of TA significantly reduces the postoperative blood loss in hip and femoral surgeries, which was indicated by volume of blood in drain and fall in hemoglobin postoperatively. A similar study was conducted by Sadeghi and Mehraein\[[@ref17]\] to see the effect of TA on hip fracture surgery. They found perioperative blood loss significantly lower in the TA group (*P*\<0.03). The total blood loss was 960±483 ml in TA group and 1484±724 ml in the control group (*P*\<0.001). Postoperative drainage was lower in TA group (296±85 ml vs. 375±110 ml, *P*\<0.195). There were no differences in coagulation parameters. The rates of transfused patients in TA and control groups were 37 % and 57%.

Other studies like of Benoni *et al*.,\[[@ref18]\] Jansen *et al*.,\[[@ref19]\] Yamasaki *et al*.,\[[@ref20]\] Ekback *et al*.,\[[@ref21]\] and Sano *et al*.,\[[@ref22]\] was conducted on THR or TKR. The volume of blood loss in these procedures may be lesser or greater than during hip fracture surgery and can be attributed to duration as well procedure, but still results were not dissimilar with our study. Benoni *et al*.\[[@ref18]\] administered TA intravenously before tourniquet release and then 3 h later in patients undergoing TKA, and reported that the intra and postoperative blood loss were reduced to one-third as a result. However, in contrast to elective hip or knee surgery; in hip fracture, the fibrinolytic system is activated by trauma and increased during surgery. So we used a single bolus dose of TA 15 min prior to skin incision followed by continuous infusion to ensure that its clot stabilize the effect would cover both the intra as well as the postoperative period.

In agreement with our findings, which were based on a surgical procedure that was of similar duration (120 min) Ekbäck *et al*. showed that the perioperative blood loss was significantly lower in the TA-treated group than in the control group. Postoperative drainage bleeding was correspondingly less (*P*=0.001) (520±280 vs. 920±410 ml).\[[@ref21]\]

Jansen *et al*.\[[@ref19]\] investigated the effect of TA on blood loss in 42 patients undergoing total knee arthroplasty. Total blood loss measured at 72 h was 678 ml in TA group while 1419 in the control group. Blood loss on discharge from PACU was 58% reduced in TA group. They also found that at first postoperative day, Hb concentration, expressed as a fraction of preoperative value was significantly higher in TA group as compared to control group (83% vs. 73%, respectively; *P*\<0.01) that itself reflect the blood loss.

Yamasaki *et al*.\[[@ref20]\] in their study on cement less THR found a reduction in total blood loss in the TA group (1349±478 ml) than in the control group (1646±469 ml) (*P*\<0.01). Their postoperative laboratory findings showed that the hemoglobin and hematocrit values on the first, seventh, and fourteenth postoperative days were significantly higher in the TA group than in the control group. In addition, the hemoglobin and hematocrit values in the TA group recovered to the first preoperative day level by the fourteenth postoperative day.

This study also demonstrates that transfusion requirements also reduced in the study group. A meta-analysis of nine randomized control trial reveals that use of TA in TKR significantly reduces the proportion of patients requiring blood transfusion.\[[@ref23]\] In another study by Camarasa Godoy *et al*.\[[@ref24]\] and Alvarez *et al*.\[[@ref25]\] found similar results. Lozano and colleagues\[[@ref26]\] found that only 17.6% patients on TA received blood transfusion in comparison to 54% in the control group. This is said that TA increase hypercoagulability and can lead to chance of thromboembolic episodes, but we did not face any abnormal finding. Benoni *et al*. also suggested that TA does not affect risk of DVT because it inhibits fibrinolysis in the wound not in circulation.

In conclusion, the present paired study demonstrated that the administration of TA given preoperatively reduces the blood loss in the first 24 h by a highly significant degree in patients undergoing surgeries for hip and femoral fractures as well it causes a significant reduction in postoperative anemia and need for transfusion among these patients. This would in turn, help avoid complications related with transfusion of blood and blood products. However, further investigation is necessary to determine the effectiveness.
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